Literature DB >> 35603127

A deep learning framework for drug repurposing via emulating clinical trials on real-world patient data.

Ruoqi Liu1, Lai Wei2, Ping Zhang1,2,3.   

Abstract

Drug repurposing is an effective strategy to identify new uses for existing drugs, providing the quickest possible transition from bench to bedside. Real-world data, such as electronic health records and insurance claims, provide information on large cohorts of users for many drugs. Here we present an efficient and easily customized framework for generating and testing multiple candidates for drug repurposing using a retrospective analysis of real-world data. Building upon well-established causal inference and deep learning methods, our framework emulates randomized clinical trials for drugs present in a large-scale medical claims database. We demonstrate our framework on a coronary artery disease cohort of millions of patients. We successfully identify drugs and drug combinations that substantially improve the coronary artery disease outcomes but haven't been indicated for treating coronary artery disease, paving the way for drug repurposing.

Entities:  

Year:  2021        PMID: 35603127      PMCID: PMC9119409          DOI: 10.1038/s42256-020-00276-w

Source DB:  PubMed          Journal:  Nat Mach Intell        ISSN: 2522-5839


  35 in total

1.  Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.

Authors:  R B D'Agostino
Journal:  Stat Med       Date:  1998-10-15       Impact factor: 2.373

Review 2.  Chronic heart failure in the United States: a manifestation of coronary artery disease.

Authors:  M Gheorghiade; R O Bonow
Journal:  Circulation       Date:  1998-01-27       Impact factor: 29.690

3.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

4.  Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial.

Authors:  M L Fisher; S S Gottlieb; G D Plotnick; N L Greenberg; R D Patten; S K Bennett; B P Hamilton
Journal:  J Am Coll Cardiol       Date:  1994-03-15       Impact factor: 24.094

5.  Effect of the angiotensin receptor blocker Valsartan on coronary microvascular flow reserve in moderately hypertensive patients with stable coronary artery disease.

Authors:  Takahiro Higuchi; Claudia Abletshauser; Stephan G Nekolla; Markus Schwaiger; Frank M Bengel
Journal:  Microcirculation       Date:  2007 Nov-Dec       Impact factor: 2.628

Review 6.  Drug repurposing: progress, challenges and recommendations.

Authors:  Sudeep Pushpakom; Francesco Iorio; Patrick A Eyers; K Jane Escott; Shirley Hopper; Andrew Wells; Andrew Doig; Tim Guilliams; Joanna Latimer; Christine McNamee; Alan Norris; Philippe Sanseau; David Cavalla; Munir Pirmohamed
Journal:  Nat Rev Drug Discov       Date:  2018-10-12       Impact factor: 84.694

7.  An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies.

Authors:  Peter C Austin
Journal:  Multivariate Behav Res       Date:  2011-06-08       Impact factor: 5.923

8.  DPDR-CPI, a server that predicts Drug Positioning and Drug Repositioning via Chemical-Protein Interactome.

Authors:  Heng Luo; Ping Zhang; Xi Hang Cao; Dizheng Du; Hao Ye; Hui Huang; Can Li; Shengying Qin; Chunling Wan; Leming Shi; Lin He; Lun Yang
Journal:  Sci Rep       Date:  2016-11-02       Impact factor: 4.379

Review 9.  A review of computational drug repositioning: strategies, approaches, opportunities, challenges, and directions.

Authors:  Tamer N Jarada; Jon G Rokne; Reda Alhajj
Journal:  J Cheminform       Date:  2020-07-22       Impact factor: 5.514

10.  Network-based approach to prediction and population-based validation of in silico drug repurposing.

Authors:  Feixiong Cheng; Rishi J Desai; Diane E Handy; Ruisheng Wang; Sebastian Schneeweiss; Albert-László Barabási; Joseph Loscalzo
Journal:  Nat Commun       Date:  2018-07-12       Impact factor: 14.919

View more
  5 in total

Review 1.  Computational drug repurposing based on electronic health records: a scoping review.

Authors:  Nansu Zong; Andrew Wen; Sungrim Moon; Sunyang Fu; Liwei Wang; Yiqing Zhao; Yue Yu; Ming Huang; Yanshan Wang; Gang Zheng; Michelle M Mielke; James R Cerhan; Hongfang Liu
Journal:  NPJ Digit Med       Date:  2022-06-14

2.  Deep Learning Promotes the Screening of Natural Products with Potential Microtubule Inhibition Activity.

Authors:  Xiao-Nan Jia; Wei-Jia Wang; Bo Yin; Lin-Jing Zhou; Yong-Qi Zhen; Lan Zhang; Xian-Li Zhou; Hai-Ning Song; Yong Tang; Feng Gao
Journal:  ACS Omega       Date:  2022-08-05

Review 3.  Drug repositioning: A bibliometric analysis.

Authors:  Guojun Sun; Dashun Dong; Zuojun Dong; Qian Zhang; Hui Fang; Chaojun Wang; Shaoya Zhang; Shuaijun Wu; Yichen Dong; Yuehua Wan
Journal:  Front Pharmacol       Date:  2022-09-26       Impact factor: 5.988

Review 4.  A review on computer-aided chemogenomics and drug repositioning for rational COVID-19 drug discovery.

Authors:  Saeid Maghsoudi; Bahareh Taghavi Shahraki; Fatemeh Rameh; Masoomeh Nazarabi; Yousef Fatahi; Omid Akhavan; Mohammad Rabiee; Ebrahim Mostafavi; Eder C Lima; Mohammad Reza Saeb; Navid Rabiee
Journal:  Chem Biol Drug Des       Date:  2022-09-22       Impact factor: 2.873

Review 5.  Machine Learning Applications in Drug Repurposing.

Authors:  Fan Yang; Qi Zhang; Xiaokang Ji; Yanchun Zhang; Wentao Li; Shaoliang Peng; Fuzhong Xue
Journal:  Interdiscip Sci       Date:  2022-01-23       Impact factor: 3.492

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.